Lazard Asset Management LLC Purchases 6,166 Shares of Regeneron Pharmaceuticals, Inc. $REGN

Lazard Asset Management LLC lifted its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 56.9% during the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 17,004 shares of the biopharmaceutical company’s stock after purchasing an additional 6,166 shares during the quarter. Lazard Asset Management LLC’s holdings in Regeneron Pharmaceuticals were worth $13,138,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also bought and sold shares of REGN. Insigneo Advisory Services LLC raised its position in Regeneron Pharmaceuticals by 3.0% during the fourth quarter. Insigneo Advisory Services LLC now owns 445 shares of the biopharmaceutical company’s stock valued at $343,000 after purchasing an additional 13 shares in the last quarter. Arjuna Capital boosted its position in Regeneron Pharmaceuticals by 3.2% during the 1st quarter. Arjuna Capital now owns 457 shares of the biopharmaceutical company’s stock valued at $353,000 after buying an additional 14 shares during the period. Guardian Wealth Advisors LLC NC boosted its holdings in shares of Regeneron Pharmaceuticals by 3.3% during the fourth quarter. Guardian Wealth Advisors LLC NC now owns 443 shares of the biopharmaceutical company’s stock worth $342,000 after purchasing an additional 14 shares during the period. TD Private Client Wealth LLC lifted its holdings in Regeneron Pharmaceuticals by 9.7% in the 4th quarter. TD Private Client Wealth LLC now owns 169 shares of the biopharmaceutical company’s stock worth $130,000 after buying an additional 15 shares during the period. Finally, MCF Advisors LLC lifted its holdings in Regeneron Pharmaceuticals by 50.0% in the 4th quarter. MCF Advisors LLC now owns 45 shares of the biopharmaceutical company’s stock worth $35,000 after buying an additional 15 shares during the period. 83.31% of the stock is owned by hedge funds and other institutional investors.

More Regeneron Pharmaceuticals News

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Potentially solid quarterly results: Investors are looking for continued growth from Dupixent, Eylea HD and Libtayo, along with updates on buybacks and Regeneron’s development pipeline. The prior quarter showed strong momentum, with revenue rising 19% year over year and EPS exceeding analyst expectations. Regeneron To Report Earnings Tomorrow
• Positive Sentiment: Partnered Arcalyst momentum: Kiniksa Pharmaceuticals exceeded second-quarter expectations, supported by sales of Arcalyst, which is partnered with Regeneron. The update may reinforce confidence in the commercial performance and royalty contribution of the collaboration, although the impact on REGN is indirect. Kiniksa Tops Q2 Estimates on Regeneron-Partnered Arcalyst
• Neutral Sentiment: Earnings are the next major catalyst: Regeneron is scheduled to report before the market opens Thursday. Investors will focus on product sales, full-year guidance, pipeline commentary and management’s response to the recent clinical setback. Regeneron to Announce Earnings on Thursday
• Negative Sentiment: Failed melanoma trial and litigation overhang: Multiple law firms announced or promoted securities class actions alleging that Regeneron and executives misled investors about the Phase 3 Fianlimab-Libtayo trial, including its protocol changes and clinical differentiation. The trial failure reportedly caused a sharp selloff and an approximately $11 billion loss in market value. The lawsuits themselves may not create an immediate cash liability, but they add reputational, legal and pipeline risk. Investors have until September 14, 2026, to seek lead-plaintiff status. Regeneron Investor Alert

Insider Activity

In related news, Director Arthur F. Ryan sold 200 shares of Regeneron Pharmaceuticals stock in a transaction dated Thursday, July 2nd. The shares were sold at an average price of $650.15, for a total transaction of $130,030.00. Following the completion of the transaction, the director directly owned 17,303 shares of the company’s stock, valued at $11,249,545.45. This trade represents a 1.14% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 6.97% of the stock is currently owned by insiders.

Analysts Set New Price Targets

REGN has been the topic of several research analyst reports. Guggenheim boosted their target price on Regeneron Pharmaceuticals from $995.00 to $1,000.00 and gave the company a “buy” rating in a research note on Tuesday, July 21st. HSBC dropped their price target on Regeneron Pharmaceuticals from $990.00 to $880.00 and set a “buy” rating for the company in a research note on Monday, July 6th. Sanford C. Bernstein reduced their price objective on shares of Regeneron Pharmaceuticals from $925.00 to $921.00 and set an “outperform” rating on the stock in a research report on Wednesday, April 8th. Canaccord Genuity Group decreased their price objective on shares of Regeneron Pharmaceuticals from $1,057.00 to $875.00 and set a “buy” rating for the company in a report on Tuesday, May 19th. Finally, Leerink Partners reaffirmed a “market perform” rating and issued a $641.00 target price (down from $792.00) on shares of Regeneron Pharmaceuticals in a research report on Monday, May 18th. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and nine have issued a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $787.88.

Regeneron Pharmaceuticals Trading Up 0.0%

NASDAQ REGN opened at $695.42 on Thursday. The firm has a market capitalization of $73.52 billion, a PE ratio of 16.94, a P/E/G ratio of 27.77 and a beta of 0.24. The stock’s 50 day moving average is $638.74 and its 200 day moving average is $711.76. Regeneron Pharmaceuticals, Inc. has a twelve month low of $541.00 and a twelve month high of $821.11. The company has a quick ratio of 2.96, a current ratio of 3.57 and a debt-to-equity ratio of 0.06.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings data on Wednesday, April 29th. The biopharmaceutical company reported $9.47 EPS for the quarter, beating the consensus estimate of $8.91 by $0.56. Regeneron Pharmaceuticals had a return on equity of 13.16% and a net margin of 29.65%.The business had revenue of $3.61 billion during the quarter, compared to analyst estimates of $3.48 billion. During the same quarter last year, the firm posted $8.22 earnings per share. The company’s revenue for the quarter was up 19.0% on a year-over-year basis. Research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 2.06 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.